Circulating Tumor Cells may be an Early Diagnostic Marker for Disease Progression in Patients with Breast Carcinoma
Keywords:
Breast cancer, cytokeratin, Circulating tumor cells, Metastatic Breast Cancer, EpCAM, CKAbstract
Background: Cancer affects millions of people around the world. In Pakistan, breast cancer (BC) is the leading cause of death in women. Once the tumor has established itself, tumor cells shed and enter the blood circulation to metastasize to distant areas of the body. These cells are known as circulating tumor cells (CTCs) and their presence in cancer patients has been documented. The current study was designed to determine CTCs in BC patients.
Methods: This was a descriptive cross-sectional study that consisted of 80 newly diagnosed females with BC. Patients were allotted different stages according to the American Joint Committee on Cancer (AJCC) staging system. Stage I comprised 11 subjects, stage II had 30, stage III 31 and stage IV included 8 subjects. After writing informed consent, 3 ml anticoagulated whole blood was collected from each patient, and transported to the Department of Immunology, University of Health Sciences (UHS), Lahore. CTCs were stained with CD45, CD326, and anticytokeratins 8, 18, 19. CTCs were analyzed by FACS calibur flow cytometer (BD) using BD Cell Quest Pro software. Data was entered and analyzed using SPSS 20.0.
Results: Twenty-three (28.7%) patients had more than 5 CTCs, while 57 (71.3%) had less than 5 CTCs in their blood samples. Mean ± SD of CTCs was high in stage IV of BC (8±7.92) as compared to stage I (1±1.67), stage II (2±2.91) and stage III (4±4.88) and on comparison there was a statistically significant difference between stage I and IV (p=0.002) and between stage II and IV (p=0.003). Mean ± SD of CTCs was high in patients with metastatic disease (8±7.92) as compared to non-metastatic disease (3±3.99) and on comparison the difference was statistically significant (p= 0.002). Mean ± SD of CTCs was high (5±5.89) in patients with family history of carcinomas including BC and other solid tumors compared to patients who did not have family history of cancer (2±3.36) and on comparison, the difference between these groups was statistically significant (p=0.016).
Conclusions: CTCs were higher in stage IV as compared to other stages of BC. CTCs were high in patients with a positive family history of BC compared to subjects without family history of BC. CTCs were higher in patients with metastatic disease as compared to non-metastatic disease.
References
1. Tariq R, Huma S, Zaka Butt M, et al. Risk factors leading to high prevalence of breast cancer. Journal of Applied Pharmacy. 2013;63(8):1075-1078.
2. Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(1):7-34.
3. Ferlay J, Shin H, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127(12):2893-2917.
4. Asif H, Sultana S, Akhtar N, et al. Prevalence, Risk Factors and Disease Knowledge of Breast Cancer in Pakistan. Asian Pacific Journal of Cancer Prevention. 2014;15(11):4411-4416.
5. Naveed S, Kamal A, Shamshad D, et al. Frequency and Risk Factors of Breast Cancer in Karachi, Pakistan. DHR International Journal of Medical Sciences. 2014;5(1).
6. Who.int. (2014). [online] Available at: https://www.who.int/cancer/country-profiles/pak_en.pdf [Accessed 2 Mar. 2019].
7. Hu Y, Fan L, Zheng J, et al. Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels. Cytometry. Part A: The Journal of the International Society for Analytical Cytology. 2010;77(3): 213–219.
8. Ring A, Smith I and Dowsett M. Circulating tumour cells in breast cancer. The Lancet Oncology. 2004;5(2):79-88.
9. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology. 2005; 23(7): 1420–1430.
10. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clinical Cancer Research. 2004;15: 6897-6904.
11. Harouaka R, Nisic M and Zheng S. Circulating Tumor Cell Enrichment Based on Physical Properties. Journal of Laboratory Automation. 2013;18(6): 455-468.
12. Hanahan D and Weinberg R. Hallmarks of Cancer: The Next Generation. Cell. 2011; 144(5): 646-674.
13. Joosse S, Gorges T and Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Molecular Medicine. 2014;7(1):1-11.
14. AF, Groom AC and MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2: 563–572.
15. Kang Y and Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013;23: 573–581.
16. Khoo LB, Lee SC, Kumar P. et al. Expansion of circulating breast cancer cells predicts response to anti- cancer therapy. Oncotarget. 2015;6(17): 15578-15593.
17. Mikolajczyk DS, Millar LS, Tsinberg P. et al. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. Journal of Oncology. 2011;1-10.
18. Cohen S, Punt C, Iannotti N, et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2008;26(19): 3213-3221.
19. Giuliano, M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011; 13(3): 67-80.
20. Harami SFM, Wisinski KB and Beebe DJ. Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. J Patient Cent Res Rev 2015;1(2): 85–92.
21. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow- up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14): 4218–4224.
22. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of Clinical Oncology. 2008;26(8):1208–15.
23. Pierga, J.Y., Bidard, F.C., Mathiot, et al. Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial. Clinical Cancer Research. 2008;14(21): 7004–7010.
24. Nakamura S, Yagata H, Ohno S, et al. Multi- center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010;17(3):199–204.
25. Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research. 2010;16(9):2634–45.
26. Boutrus RR, Abi Raad RF, Kuter I, et al. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers.2013;28(1):17–23.
27. Bidard F, Proudhon C, Pierga J. Circulating tumor cells in breast cancer. Molecular oncology. 2016;10(3): 418-430.
28. Hortobagyi G, Connolly J, D’Orsi C, et al. Breast. AJCC Cancer Staging Manual. 2017;589-636.
29. Ried K, Eng P. and Sali A. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. Advances in Cancer Prevention. 2017;18(8): 2275–2285.
30. Ilie M, Hofman V, Long-Mira E, et al. “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE. 2014;9(10):111597.
31. Castro J, Sanchez L, Nuñez M, et al. Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2). Disease Markers.2018;2018:1-5.
32. Maestro LM, Sastre J, Rafael SB, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer research. 2009;29(11):4839-4843.
33. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129(7):1651–1660
34. Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Annals of Oncology. 2008;19(5):891-897.
35. De Giorgi U, Valero V, Rohren, E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology. 2009;21(1): 33-39.
36. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research. 2014;16(5).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Marwah Minhas, Neelam Majeed, Romeeza Tahir, Faheem Shahzad, Muhammad Kashif, Nadeem Afzal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under a CC-BY 4.0 License.
